Dostarlimab: From preclinical investigation to drug approval and future directions

• Váldodahkkit: Carlo Maria Cicala (Dahkki), Lucia Musacchio (Dahkki), Giovanni Scambia (Dahkki), Domenica Lorusso (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2023-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Immune checkpoint blockers (ICB) act by reverting the immunosuppressive phenotype of cancer cells, thus allowing host immune system to generate an immune response to the tumor. One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which lies onto the interaction between the programmed-ce...